News & Events about Avrobio Inc.
Business Wire
6 months ago
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in a panel titled Orphan Neuro Corporate Panel at Cowens 43rd Annual Health...
AVROBIO, Inc. (NASDAQ:AVRO Get Rating) Investment analysts at Wedbush issued their Q1 2023 earnings per share estimates for AVROBIO in a report issued on Tuesday, May 10th. Wedbush analyst D. Nierengarten forecasts that the company will earn ($0.29) per share for the quarter. Wedbush...
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of up to 63,000 shares of the companys common stock to one...
Wall Street analysts predict that AVROBIO, Inc. (NASDAQ:AVRO Get Rating) will report earnings of ($0.71) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for AVROBIOs earnings, with estimates ranging from ($0.76) ...